Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128707 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL24142320 | 0.86 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15463431 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10110895 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29456842 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2605919 | 0.83 | CA1 (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| Trifluoroacetic Acid SCHEMBL7518693 | 0.83 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14035924 | 0.82 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14009338 | 0.82 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL515519 | 0.82 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-117750981-A | Peptides comprising N-formyl-halomethionine residues and engineered antibody-peptide conjugates thereof | 伊莱利利公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-116640182-A | Transdermal delivery system for polypeptides and related compounds | 泰飞尔生物医药(苏州)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KMT2A 4608/4885FABP5 2565/4885FABP7 3166/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KMT2A 4608/4885FABP5 2565/4885FABP7 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.